pharma · Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) · IgA Nephropathy (IgAN) · VERA
Vera Therapeutics
Vera Therapeutics clinical programs — 13 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 4539 Metropolitan Ct, Frederick, Maryland 21704, US
- Founded
- 2018
- Employees
- 9
- Programs
- 25
- Drugs
- 32
- Patents
- 140
Vera Therapeutics projects
13 ClinicalTrials.gov programs sponsored by Vera Therapeutics.
Vera Therapeutics has 13 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Analogs, Prostaglandin E1
Vera Therapeutics
Covid19
1 trial -
Atacicept
Vera Therapeutics
IgA Nephropathy (IgAN)
1 trial -
Atacicept
Vera Therapeutics
IgA Nephropathy (IgAN); Berger Disease; Renal and Urinary Disorders
1 trial -
Atacicept
Vera Therapeutics
pMN
1 trial -
Atacicept 150 mg
Vera Therapeutics
IgA Nephropathy (IgAN)
1 trial -
Atacicept Autoinjector Combination, Atacicept
Vera Therapeutics
Treatment of IgAN
1 trial -
Atacicept Autoinjector Combination, Atacicept
Vera Therapeutics
Multiple Autoimmune Glomerular Diseases
1 trial -
Capecitabine
Vera Therapeutics
Breast Cancer
1 trial -
Genomically Directed Monotherapy
Vera Therapeutics
Malignant Neoplasm of Breast
1 trial -
Herzuma
Vera Therapeutics
HER2 Enriched Subtype Breast Cancer, Herzuma, PAM50 Study
1 trial -
MAU868
Vera Therapeutics
BK Virus Infection
1 trial -
NestaCell®
Vera Therapeutics
COVID-19 Pneumonia
1 trial -
VS-6766, VS-6063
Vera Therapeutics
Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
1 trial
Frequently asked questions
How many clinical projects does Vera Therapeutics have?
13 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.